.Pharmacolibrary.Drugs.ATC.L.L04AA24 .Pharmacolibrary.Drugs.ATC.L.L04AA24| name: | Abatacept |
| ATC code: | L04AA24 | route: | intravenous |
| n-compartments | 2 |
Abatacept is a selective T-cell co-stimulation modulator used for the treatment of moderate to severe rheumatoid arthritis and other autoimmune diseases. It is a fusion protein composed of the extracellular domain of human cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) linked to the modified Fc portion of human IgG1. Abatacept is approved and widely used in clinical practice.
Pharmacokinetics in adult rheumatoid arthritis patients following intravenous administration at a dose of ~10 mg/kg; parameter values represent commonly reported population means.
Li, X, et al., & Murthy, B (2019). Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis. Journal of clinical pharmacology 59(2) 245–257. DOI:10.1002/jcph.1308 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30229926
Balevic, SJ, et al., & Hornik, CP (2024). Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA network open 7(4) e247615–None. DOI:10.1001/jamanetworkopen.2024.7615 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38662372
Lon, HK, et al., & Jusko, WJ (2013). Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. Journal of pharmacokinetics and pharmacodynamics 40(6) 701–712. DOI:10.1007/s10928-013-9341-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24233383